These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 16097091)

  • 41. [Detection of side effects. 2: Responsibilities of the pharmaceutical industry, drug commissions, the Federal Health Office and international organizations].
    Gleiter CH; Bieck PR
    Fortschr Med; 1991 Jul; 109(21):429-31. PubMed ID: 1916572
    [No Abstract]   [Full Text] [Related]  

  • 42. International Conference on Harmonisation; guidance on Q10 Pharmaceutical Quality System; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Apr; 74(66):15990-1. PubMed ID: 19507321
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Botanical drugs: a future for herbal medicines.
    Li W
    J Contemp Health Law Policy; 2002; 19(1):117-49. PubMed ID: 12733224
    [No Abstract]   [Full Text] [Related]  

  • 44. Indian Supreme Court halts approval of new clinical trials until regulatory framework is set up.
    Bagcchi S
    BMJ; 2013 Oct; 347():f5996. PubMed ID: 24097130
    [No Abstract]   [Full Text] [Related]  

  • 45. Trouble at the office.
    Allison M
    Nat Biotechnol; 2008 Sep; 26(9):967-9. PubMed ID: 18779797
    [No Abstract]   [Full Text] [Related]  

  • 46. Regulators scramble to tighten loopholes after heparin debacle.
    Jia H
    Nat Biotechnol; 2008 May; 26(5):477-8. PubMed ID: 18464756
    [No Abstract]   [Full Text] [Related]  

  • 47. Amendments to the Canadian Patent Act to address drug access: is help on the way?
    Penner MD; Narayanan P
    Food Drug Law J; 2005; 60(3):459-70. PubMed ID: 16304751
    [No Abstract]   [Full Text] [Related]  

  • 48. A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
    McCabe AR
    Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844
    [No Abstract]   [Full Text] [Related]  

  • 49. Equivocal role of micelles in Eprex adverse events.
    Smiell JM
    Nat Biotechnol; 2003 Nov; 21(11):1265; author reply 1266. PubMed ID: 14595347
    [No Abstract]   [Full Text] [Related]  

  • 50. Equivocal role of micelles in Eprex adverse events.
    Schellekens H; Crommelin DJ
    Nat Biotechnol; 2003 Nov; 21(11):1265; author reply 1266. PubMed ID: 14595346
    [No Abstract]   [Full Text] [Related]  

  • 51. Tysabri's troubles return.
    Hoag H
    Nat Biotechnol; 2008 Oct; 26(10):1061. PubMed ID: 18846062
    [No Abstract]   [Full Text] [Related]  

  • 52. Applications for Food and Drug Administration application approval to market a new drug; revision of postmarketing reporting requirements. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2007 Oct; 72(201):58993-9000. PubMed ID: 17966558
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tuft's report backs FDA fast-track, but post-marketing concerns loom.
    Vastag B
    Nat Biotechnol; 2006 May; 24(5):478. PubMed ID: 16680113
    [No Abstract]   [Full Text] [Related]  

  • 54. European ombudsman questions European Medicines Agency over AbbVie redactions.
    Watson R
    BMJ; 2014 Nov; 349():g6904. PubMed ID: 25406123
    [No Abstract]   [Full Text] [Related]  

  • 55. Public policy implications of cross-border Internet pharmacies.
    Cohen JC
    Manag Care; 2004 Mar; 13(3 Suppl):14-6. PubMed ID: 15074164
    [No Abstract]   [Full Text] [Related]  

  • 56. "Top 10" trends predictions were 100 percent accurate for year 2000.
    Coile RC
    Russ Coiles Health Trends; 2001 Jan; 13(3):2-4. PubMed ID: 11209187
    [No Abstract]   [Full Text] [Related]  

  • 57. The rise and fall of Natrecor for congestive heart failure: implications for drug policy.
    Kesselheim AS; Fischer MA; Avorn J
    Health Aff (Millwood); 2006; 25(4):1095-102. PubMed ID: 16835191
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mandatory post marketing studies.
    Somberg J
    Am J Ther; 2007; 14(4):321. PubMed ID: 17667203
    [No Abstract]   [Full Text] [Related]  

  • 59. Canaries, coal mines and the drug supply.
    Leiden JM
    Nat Biotechnol; 2008 Jun; 26(6):624-6. PubMed ID: 18536681
    [No Abstract]   [Full Text] [Related]  

  • 60. Clinical trials registration efforts gain some ground.
    Zielinski SL
    J Natl Cancer Inst; 2005 Mar; 97(6):410-1. PubMed ID: 15769999
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.